In order to evaluate the impairment of GH response in patients affected by Prader-Labhardt-Willi (PLW) syndrome, in 18 patients we studied GH response to clonidine and to GHRH + pyridostigmine, a cholinergic drug which enhances GHRH induced GH responsiveness in obese patients. After clonidine GH response was abnormal in 14/18 subjects (mean GH peak: 4.1 +/- 1.3 micrograms/l; area under curve: 208.1 +/- 74.2 micrograms/l.h) while all but 5 patients showed an inadequate GH response to GHRH + pyridostigmine (mean GH peak: 13.4 +/- 2.5 micrograms/l; area under curve: 903.4 +/- 171.0 micrograms/l.h). However, in the three patients with low adiposity index, GH response to GHRH + pyridostigmine was significantly higher than that observed in fatter subjects. In addition, GH response to GHRH + pyridostigmine was negatively correlated to age and adiposity index. In conclusion, our data are consistent with the hypothesis of the existence of a complex derangement of GH neuroendocrine regulation in these subjects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF03349040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome.
Horm Res Paediatr
December 2014
Autoimmune Endocrine Diseases Unit, Endocrinology Department, Bambino Gesù Children's Hospital, Research Institute, Palidoro (Rome), Italy.
Background: In Prader-Willi syndrome (PWS) a reduced growth hormone (GH) response to several stimulators has been documented in many studies, but none have focused on very young children. We evaluated the pattern of GH secretion in very young PWS patients.
Patients And Methods: Twenty-seven genetically confirmed PWS children (10 females, aged 0.
Prevalence of posttraumatic growth hormone deficiency is highly dependent on the diagnostic set-up: results from The Danish National Study on Posttraumatic Hypopituitarism.
J Clin Endocrinol Metab
January 2014
Department of Medical Endocrinology (M.K., U.F.-R.), Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark; Department of Internal Medicine and Endocrinology (K.S., J.J., J.F., J.S.C.), Aarhus University Hospital, DK-8000 Aarhus, Denmark; Department of Medical Endocrinology (L.L.C., M.A.), Odense University Hospital, DK-5000 Odense, Denmark; and Department of Medical Endocrinology (P.L.), Aalborg University Hospital, DK-9100 Aalborg, Denmark.
Context: Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias.
Objective: Our objective was to assess the prevalence of GHD in patients admitted in 2008 with TBI, with concurrent assessment of methodological bias.
The effect of body mass index on the diagnosis of GH deficiency in patients at risk due to a pituitary insult.
Eur J Endocrinol
January 2010
Department of Endocrinology, Evangelismos Hospital, Athens, Greece.
Objectives: Diminished GH response to stimulation has been demonstrated in obesity, leading to erroneous diagnosis of GH deficiency. The aim of this study was to evaluate the influence of body mass index (BMI) on GH responsiveness in patients at risk for pituitary function deficits.
Methods: A total of 59 healthy subjects and 75 patients with a pituitary insult underwent insulin tolerance test or pyridostigmine+GHRH test in order to assess GH secretory reserve.
An inhibition of the hypothalamic somatostatinergic tone is not the cause of the enhanced growth hormone response to growth hormone-releasing hormone in patients with liver cirrhosis.
Exp Clin Endocrinol Diabetes
March 2008
Dipartimento-Struttura Clinica Medica - Patologia Speciale Medica, University of Sassari, Sassari, Italy.
Animal models of liver cirrhosis (LC) display a reduced hypothalamic somatostatinergic tone. To test whether a similar mechanism could explain the enhanced Growth Hormone (GH) secretory response to GH-Releasing Hormone (GHRH), which is seen in human LC, we studied the effect of the cholinesterase inhibitor pyridostigmine (PD), which is able to reduce the release of hypothalamic somatostatin (SS), on the GHRH-stimulated GH secretion. We considered that if PD were unable to increase GH secretion, this would constitute evidence of an already inhibited endogenous somatostatinergic tone.
View Article and Find Full Text PDFPioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
J Clin Endocrinol Metab
October 2005
Department of Endocrinology and Metabolism, Odense University Hospital, Denmark.
Background: Low GH levels, probably due to insulin resistance and increased abdominal fat mass, are well described in polycystic ovary syndrome (PCOS). GH acts as an important ovarian cogonadotropin, and GH disturbances may be an additional pathogenic factor in PCOS. Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!